N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma

Li, Tingshen; Yu, Peng; Chen, Yi-Hao; Sun, Baoying; Dong, Peijie; Zhu, Tao; Meng, Xin

doi:10.1016/j.ejmech.2021.113605

Cited by 23 publications

(10 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of such nanocarriers depends on the delivery and residence at the intended target site, as well as the degree of vascularity and arterial anatomy. Promising early experimental in vitro results have been reported from a novel asialoglycoprotein receptor targeted PEGylated paclitaxel nanoliposome for HCC that exhibited enhanced cytotoxicity compared to free paclitaxel and improved cellular uptake level based on the EPR effect [ 123 ]. Significant research and development is needed to improve the success of these translational findings from in vitro to in vivo and eventually to clinical use.…”

Section: The Future Of Tacementioning

confidence: 99%

Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma

Barbier

Heindryckx

Lennernäs

2021

IJMS

View full text Add to dashboard Cite

Because diagnostic tools for discriminating between hepatocellular carcinoma (HCC) and advanced cirrhosis are poor, HCC is often detected in a stage where transarterial chemoembolization (TACE) is the best treatment option, even though it provides a poor survival gain. Despite having been used worldwide for several decades, TACE still has many limitations. First, there is a vast heterogeneity in the cellular composition and metabolism of HCCs as well as in the patient population, which renders it difficult to identify patients who would benefit from TACE. Often the delivered drug does not penetrate sufficiently selectively and deeply into the tumour and the drug delivery system is not releasing the drug at an optimal clinical rate. In addition, therapeutic effectiveness is limited by the crosstalk between the tumour cells and components of the cirrhotic tumour microenvironment. To improve this widely used treatment of one of our most common and deadly cancers, we need to better understand the complex interactions between drug delivery, local pharmacology, tumour targeting mechanisms, liver pathophysiology, patient and tumour heterogeneity, and resistance mechanisms. This review provides a novel and important overview of clinical data and discusses the role of the tumour microenvironment and lymphatic system in the cirrhotic liver, its potential response to TACE, and current and possible novel DDSs for locoregional treatment.

show abstract

Section: The Future Of Tacementioning

confidence: 99%

Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma

Barbier

Heindryckx

Lennernäs

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…GA-WG-Lip also improved cellular uptake and tumor recognition. The other ligands also showed good targeting and were modified on the liposome to deliver natural products, such as tLyp-1 (sequence CGNKRTR) ( Jin et al, 2018 ), transferrin ( Leto et al, 2016 ), and monosaccharide GalNAc with α configuration (Tn antigen) ( Li et al, 2021a ).…”

Section: Construction Of Liposomal Systems For Medicinal Natural Prod...mentioning

confidence: 99%

“…Taxanes with a tetracyclic diterpene, including paclitaxel (Taxol ® ) and its synthetic analog docetaxel (Taxotere ® ) have shown antitumor activity by inhibition of microtubules and cell division. The temperature-sensitive liposomes (PTX-TSL) modified with K237 peptide enhanced the cellular uptake and cytotoxicity of paclitaxel against cancer cells and endothelial cells ( Fu et al, 2019a ; Li et al, 2021a ). N -acetylgalactosamine modified liposome (Tn-Lipo-PTX) improved the targeted cytotoxicity to HepG2 cells.…”

Section: Construction Of Liposomal Systems For Medicinal Natural Prod...mentioning

confidence: 99%

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

et al. 2022

View full text Add to dashboard Cite

Although medicinal natural products and their derivatives have shown promising effects in disease therapies, they usually suffer the drawbacks in low solubility and stability in the physiological environment, low delivery efficiency, side effects due to multi-targeting, and low site-specific distribution in the lesion. In this review, targeted delivery was well-guided by liposomal formulation in the aspects of preparation of functional liposomes, liposomal medicinal natural products, combined therapies, and image-guided therapy. This review is believed to provide useful guidance to enhance the targeted therapy of medicinal natural products and their derivatives.

show abstract

“…That vehicle improved drug efficacy and tumor site accumulation, while reducing drug toxicity. 75 Zhang et al constructed a Lupeol-loaded liposome system (Gal-lupeol-L system) using lactoferrin as the target ligand to deliver Lupeol to ASGPR-expressing HCC cells. In vivo and in vitro experiments revealed the good tumor-suppressive effects of that liposome system.…”

Section: Use Of Liposomesmentioning

confidence: 99%

Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer

Zhang

et al. 2022

IJN

View full text Add to dashboard Cite

The mortality rate of liver cancer is gradually increasing worldwide due to the increasing risk factors such as fatty liver, diabetes, and alcoholic cirrhosis. The diagnostic methods of liver cancer include ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI), among others. The treatment of liver cancer includes surgical resection, transplantation, ablation, and chemoembolization; however, treatment still faces multiple challenges due to its insidious development, high rate of recurrence after surgical resection, and high failure rate of transplantation. The emergence of liposomes has provided new insights into the treatment of liver cancer. Due to their excellent carrier properties and maneuverability, liposomes can be used to perform a variety of functions such as aiding in imaging diagnoses, combinatorial therapies, and integrating disease diagnosis and treatment. In this paper, we further discuss such advantages.

show abstract

N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma

Cited by 23 publications

References 53 publications

Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma

Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer

Contact Info

Product

Resources

About